Team
Key Management.
CHIEF EXECUTIVE OFFICER AND EXECUTIVE CHAIRMAN
Peter Pursey AM 
Peter is an experienced senior executive and has led the development and strategic direction of the company for over 15 years. His extensive network extends to global leaders in all phases of drug development, regulatory, pricing and marketing experts. The PresSura team now comprises leading scientists and drug development and clinical personnel from all over the world.
HEAD OF DRUG DEVELOPMENT
Dr Pierre Vankan 
Pierre was a global project leader and lifecycle leader in Hoffmann-La Roche for 10 years and has extensive experience in drug development and the implementation of drug development plans from pre-clinical through to Phase 3 clinical trials. He was Head of Development of Santhera Pharmaceuticals in Switzerland before commencing his own consulting business. Pierre has led the drug development programs in the company over the last 7 years and was associated with the company for some years before taking up his current appointment. Pierre has a very extensive global network across every sector of the drug development industry.
PHASE 2 CLINICAL DEVELOPMENT
Dr Julian Gray
After working as Head of Alzheimer research at Hoffman-La Roche in Basel, Julian went on to specialise in neurology and pharmacology. Since becoming an independent consultant in 2004, he has led numerous major large scale clinical studies and human trials as a medical expert in clinical research relating to the Central Nervous System. Julian has led all clinical and medical aspects for PresSura’s Ph 2A trial.
CLINICAL PHARMACOLOGY
Dr Klaus Kutz
Led PresSura Phase 1 development; Professor of Medicine; extensive industry experience.
REGULATORY
Dr Karl Burgin
Senior and operational roles including Roche and Chugai; founded his own regulatory advisory firm in 2010.
DATA MANAGEMENT
McCloud Consulting Group
Specialist biometrics consultancy; statistical consulting and clinical data management for regulated programmes.
Board of Directors.
Peter Pursey AM (Chairman) 
Peter is experienced in corporate governance, senior executive management, leadership, capital raising and strategic planning. He has served on a number of public company and ASX listed company boards as a director, chairman and executive chairman. He has extensive experience in the mining services, energy storage and medical diagnostics industry sectors.
John Higgins AO
John is an experienced businessman with extensive experience in the international business environment. He holds chair and director appointments across a number of business industry sectors in Australia and overseas.
Peter Higgins
Peter’s business experience brings objective perspective and external expertise to our board. His strategic inputs help guide the company’s development and protect investor interests.
Dr John Hughes
John has academic and industrial training in microbial genetics and molecular biology (Monash University, Yale University and Genentech Inc). He was a Patent Attorney at Scully Scott Murphy & Presser in the US and then a Patent Attorney and Principal at Davies Collison Cave, Patent Attorneys, where he was based in Melbourne, Brisbane and Singapore. John specialised in the protection of innovation in all facets of biotechnology including chemical, peptide and nucleic acid pharmaceutical formulations, immunotherapy and diagnostic assays.
Professor Robert Vink AM 
Robert is an international authority in brain injury whose research findings underpin the drug development program in the company. With over 300 research publications, he was awarded a DSc from the University of Adelaide for his international impact in brain injury research and was subsequently elected as a Fellow of the Australian Academy of Health and Medical Sciences. He has held numerous senior positions in academia, company boards and learned societies, including being the President of the International Neurotrauma Society. Professor Vink is a Member of the Order of Australia for contributions to neurotrauma research, education and community service.
DSMB
PresSura’s safety management board is a highly experienced and globally recognised set of independent experts.